Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amag Pharmaceuticals (AMAG) and T2 Biosystems (TTOO).
Amag Pharmaceuticals (AMAG)
Needham analyst Serge Belanger maintained a Hold rating on Amag Pharmaceuticals today. The company’s shares closed last Thursday at $7.47.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 5.6% and a 50.8% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Hold analyst consensus rating for Amag Pharmaceuticals with a $8.83 average price target, a 19.2% upside from current levels. In a report issued on May 11, Jefferies also maintained a Hold rating on the stock with a $9.00 price target.
See today’s analyst top recommended stocks >>
T2 Biosystems (TTOO)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on T2 Biosystems, with a price target of $2.50. The company’s shares closed last Thursday at $0.65, close to its 52-week low of $0.24.
According to TipRanks.com, Roy is a 5-star analyst with an average return of 21.3% and a 49.2% success rate. Roy covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Adaptimmune Therapeutics, and Monopar Therapeutics Inc.
Currently, the analyst consensus on T2 Biosystems is a Moderate Buy with an average price target of $2.75.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.